Derivative exercise or conversion — not an open-market buy.
Loading…
Holdings as of Jun 30, 2026 (Q2 2026) · Filed Aug 14, 2026
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
Exited
Compared with the manager's Q1 2026 13F
6,835
0
-100.0%
Share count drives classification; reported value also moves with price
1
For Q2 2026
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Director sold ~$10.1M of Charles River Laboratories
Scheduled in advance